MALDI-MS

With the exception of Thermo Fisher Scientific, which released three new instruments, vendors focused mainly on expanded applications of existing platforms.

By Adam Bonislawski
Biodesix said this week that it is collaborating with pharma firm Kadmon on a 620-patient Phase III clinical trial of that company's reversible tyrosine kinase inhibitor KD019.

By Adam Bonislawski
Bio-Rad has developed a workflow linking surface plasmon resonance to MALDI mass spectrometry that could offer a more sensitive and streamlined alternative to conventional SPR-MS techniques.

ProteoMonitor spoke to Cristobal Belda-Iniesta, head of the Biomarkers and Experimental Therapeutics for Cancer Group at Madrid's University Hospital La Paz, about his work applying proteomics to guide cancer therapy.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.